Skip to content

Extracorporeal Shockwave Therapy in Insertional Achilles Tendinopathy

Extracorporeal Shockwave Therapy in Insertional Achilles Tendinopathy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03683641
Enrollment
30
Registered
2018-09-25
Start date
2016-07-04
Completion date
2018-07-31
Last updated
2018-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insertional Achilles Tendinopathy

Keywords

Insertional Achilles Tendinopathy, Extracorporeal Shock Wave Therapy, Double-blind Randomized Controlled Trial

Brief summary

There is still limited number of studies in the literature provides insufficient evidence to support the use of ESWT in the treatment of insertional Achilles tendinopathy and the contribution of a placebo effect to the shock waves was not assessed by previous study. So the investigators conducted a double-blinded randomized-controlled trial at the orthopedic out-patient clinic, Department of Orthopedics, Faculty of Medicine Ramathibodi Hospital between December 2016 and June 2018. Hypothesized that ESWT might be effective on insertional Achilles tendinopathy

Detailed description

Participants aged 18-70 years old who were diagnosed as insertional Achilles tendinopathy by foot and ankle specialists: had symptoms of pain and swelling at Achilles insertion more than 6 months; failed other standard conservative treatments for 3 months, i.e., rest, medication, activity modification, stretching exercise, and heel lift orthosis; be able to complete questionnaires; and willing to participate were enrolled. A computerized block-of-four random numbers were generated into 2 groups; ESWT and placebo (sham) group. Investigators concealed the treatment allocation by sequential sealed opaque envelops. The sealed opaque envelops were opened just before the assigned treatment began. The outcome assessment in this study was seven times at pre-intervention, 2nd, 3rd, 4th, 6th, 12th and 24th weeks. The participants had to complete questionnaire of VAS and VAS-FA Thai version. The investigators used mean and standard deviation for continuous variables, and frequency (%) for categorical data. For non-normally distributed variables, median and range was presented. Continuous data of both interventions was compared using either unpaired t-test or Mann-Whitney U test based on normal distribution. While categorical data was compared using Fisher's exact test. Repeated measures with Bonferroni post hoc analysis was applied for each intervention according to times of follow-up, and between groups. Bartlett's test for equal variances was checked the assumption before using analysis of variance. If the data did not meet the assumption, non-parametric Kruskal-Wallis was performed. The investigators used STATA 15.0 Program, College Station, Texas, USA for all statistical analysis. P-value \< 0.05 defined as a significant level. Sample size was estimated using STATA 15.0 Program based on alpha error 0.05, beta error 0.2, mean VAS in controls 5.0, mean VAS in intervention group 3.5, standard deviation (SD) of both group 2.3,(13) pre-intervention assessment for 1 time, post-intervention assessment for 6 times, correlation between the first and the last VAS assessment 0.8. The calculated sample size was 12 per group. With 20% increment for loss of follow-up, the final sample size was 15 per group. All of them remained in the randomized groups and analyzed as intention-to-treat basis.

Interventions

DEVICEExtracorporeal Shock Wave Therapy

Use ESWT on chronic insertional Achilles tendinopathy

Use sham ESWT on chronic insertional Achilles tendinopathy

Sponsors

Mahidol University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Diagnosed as insertional Achilles tendinopathy * Have symptom at least 6 months * Willing to participate

Exclusion criteria

* History of peritendinous steroid injections within 4 weeks * Neurological conditions * Local skin infection * Ankle arthritis, traumatic, inflammation or deformity of ankle * History of ankle surgery * Contraindication for ESWT : Hemophilia, Coagulopathy

Design outcomes

Primary

MeasureTime frameDescription
Visual Analog ScaleUp to 24 weeksVisual Analog Scale of Pain on Achilles tendon, range 0-10, 0 means no pain and 10 is the most severe pain

Secondary

MeasureTime frameDescription
Visual Analog Scale - Foot and Ankle Thai versionUp to 24 weeksRange 0-100, 0 is worse, 100 is the best. Having 20 questions. Categorized into Pain, Function and other complaints
The amount of rescue drug useUp to 24 weeksTablet/day,if amount of drug use is higher mean it is worse
ComplicationsUp to 52 weeksInvestigator collected complication such as pain during procedure, tendon rupture, or surgical rate and calculated the NNH

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026